Par Pharmaceutical Companies, Inc. has entered into a collaborative agreement with Spectrum Pharmaceuticals, Inc. to develop and market generic drugs, including generic versions of injectable and ophthalmic pharmaceuticals. ANDAs have been filed on several of the products subject to the agreement and other product candidates are currently in development or will be subject to future development. Among the products included in the agreement is sumatriptan succinate injection, the generic ver...